Srinivas Rangu, MD
Internal Medicine · Longview, TXNPI 1902963655
Payments from drug & device makers
Across 253 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$872
- Pfizer$542
- GSK$535
- Novo Nordisk$511
- Bayer$224
- Novartis$130
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,96797%
- Education$1313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $872 |
| Pfizer | 43 | $542 |
| GSK | 39 | $535 |
| Novo Nordisk | 55 | $511 |
| Bayer | 13 | $224 |
| Novartis | 7 | $130 |
| Amarin Pharma, Inc. | 7 | $126 |
| Astellas Pharma US Inc | 2 | $107 |
| Boehringer Ingelheim | 5 | $101 |
| Sumitomo Pharma America, Inc. | 6 | $100 |
| Johnson & Johnson | 5 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $88 |
| Merck | 5 | $78 |
| Lilly USA, LLC | 5 | $70 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Amgen | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Boston Scientific | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| AbbVie | 2 | $33 |
| Abbott | 2 | $31 |
| Cashflow Solutions, LLC | 1 | $29 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Abiomed | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| GE HealthCare | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$354
- FARXIGA$244
- SYMBICORT$101
- BEVESPI AEROSPHERE$101
How this compares
$4,098 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 404 | $480,450 |
| MounjaroTirzepatide | 201 | $248,452 |
| EliquisApixaban | 250 | $224,427 |
| JardianceEmpagliflozin | 154 | $154,052 |
| JanuviaSitagliptin Phosphate | 97 | $99,477 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $59,120 |
| XareltoRivaroxaban | 50 | $44,297 |
| FarxigaDapagliflozin Propanediol | 38 | $39,936 |
| TrulicityDulaglutide | 30 | $32,452 |
| MyrbetriqMirabegron | 37 | $26,859 |
| VivitrolNaltrexone Microspheres | 13 | $20,556 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 32 | $10,874 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,650 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $10,322 |
| Nebivolol Hcl | 191 | $10,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $511 | $480,450404 claims |
| Lilly USA, LLCMounjaro, Trulicity | $70 | $280,904231 claims |
| PfizerEliquis | $542 | $224,427250 claims |
| Boehringer IngelheimJardiance | $101 | $154,052154 claims |
| MerckJanuvia, Janumet Xr, Janumet | $78 | $118,454128 claims |
| Johnson & JohnsonXarelto | $90 | $44,29750 claims |
| AstraZenecaFarxiga | $872 | $39,93638 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $26,85937 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $13 | $10,87432 claims |
| GSKTrelegy Ellipta | $535 | $9,13815 claims |
| Sanofi-aventis U.S. LLCLantus | $33 | $5,63614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Longview
- Kathleen HarrisLongview$3.1M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.